MyVisionTest News Archive

Displaying news items tagged with Avastin (More tags »)
SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last

Avastin
Apr 22, 2011
Avastin (bevacizumab) is the most popular pharmacological treatment for neovascular age-related macular degeneration (AMD) among Medicare fee-for-service beneficiaries in the United States. Over the past 3 years, both Avastin (bevacizumab) and Lucentis (ranibizumab) have emerged as the most common therapies for neovascular AMD as reported by...

Full Article


Intravitreal injection
Mar 8, 2011
To evaluate the amount of reflux and degree of pain with intravitreal injection (IVT) using 6 different types of syringes/needles and 5 techniques of scleral incision, including 3 modifications of a beveled scleral incision. The risk of serious adverse events reported after intravitreal (IVT) injection injection is low. Endophthalmitis, which...

Full Article


Children
Feb 27, 2011
Anti-VEGF drugs were safe and effective in the treatment of choroidal neovascular membranes (CNVMs) secondary to a variety of etiologies in 4 children, according to a new study. In the pediatric population, the diagnosis and management of choroidal neovascular membranes (CNVM) is challenging. Pediatric CNVMs are an infrequent but significant...

Full Article


CCTV low vision aid
Feb 27, 2011
A new study finds that Lucentis (ranibizumab) significantly improves the vision of patients with very poor baseline visual acuity secondary to neovascular age-related macular degeneration (AMD). Treatment with anti-VEGF drugs has become the standard treatment of choroidal neovascularisation (CNV) because of AMD. However, information is limited...

Full Article


Uveitis
Feb 27, 2011
Intravitreal injections with anti-VEGF agents such as Avastin (bevacizumab) and Lucentis (ranibizumab) have been increasingly used for the treatment of retinal disorders over the past years. Although both drugs are often repeatedly injected in patients with choroidal neovascularizations, serious adverse events are rare. Here, is presented a case...

Full Article


Avastin
Feb 27, 2011
Avastin (bevacizumab) is effective in the treatment of parapapillary choroidal neovascularization (CNV), according to a new study. Parapapillary CNV represent an uncommon type of neovascularization that can be associated with several ocular diseases, of which age-related macular degeneration (AMD) is the most common one. Visual acuity was...

Full Article


National Health Service
Feb 27, 2011
The North East Treatment Advisory Group (NETAG) has produced an appraisal of bevacizumab (Avastin) and ranibizumab (Lucentis), in the management of macular oedema secondary to retinal vein occlusion and recommended that bevacizumab 1.25 mg using a 'when required' (PRN) regimen is recommended for use within NHS North East as this regimen is...

Full Article


cardiovascular system
Feb 27, 2011
There is evidence of increased risk of stroke and hemorrhage associated with intravitral Lucentis (ranibizumab) therapy of age-related macular degeneration (AMD), and insufficient evidence of Avastin (bevacizumab) safety, according to a major review of the literature. In some patients treated with systemic anti–VEGF-A agents, inhibition of...

Full Article


Uveitis
Feb 26, 2011
The rate of endophthalmitis following intravitreal injection of anti-VEGF agents was very low during a recent study, a speaker said at the Macula 2011 meeting. In a 6-year retrospective case series, Streptococcus isolates presented three to four times more frequently after intravitreal injection than after intraocular surgery, Harry W. Flynn...

Full Article


Avastin
Feb 26, 2011
Utilizing a treat-and-extend treatment regimen for Avastin (bevacizumab) and Lucentis (ranibizumab) therapy proved visually efficacious as well as time- and cost-efficient among patients with neovascular age-related macular degeneration (AMD), a speaker said at the Macula 2011 meeting. While visual outcomes and recurrence rates were similar for...

Full Article


SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last
Most Popular
Less - past - More